PEG-rhGH

Phase 3Small molecule

Changchun GeneScience Pharmaceutical Co., Ltd.

PEG-rhGH is one of 5 small molecule programs targeting Short stature. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Short StatureActive, not recruiting

Cognitive DevelopmentRecruiting

Short StaturePreclinical

Active, not recruiting

Cognitive DevelopmentPhase 3

Recruiting

Competition

Competitive Landscape

4 competitors in Short Stature

#DrugCompanyPhaseTrials

Voxzogo

BioMarin Pharmaceutical

Phase 2

2 2

PEG-rhGH

Changchun GeneScience Pharmaceutical Co., Ltd.

Phase 3

1 3

PEG-Somatropin

Changchun GeneScience Pharmaceutical Co., Ltd.

Phase 2

2 4

Recombinant Human Growth Hormone

Changchun GeneScience Pharmaceutical Co., Ltd.

Preclinical

3 5

Gnrha

SSecond Affiliated Hospital of Wenzhou Medical University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Recruiting

Small for Gestational Age

NCT07260500

N/ANot yet recruiting

Short Stature

NCT06768411

Clinical

Trials by Indication[1]

Small for gestational age1 trial

A Phase II Study of PEG-rhGH Injection for Short Children Born Small for Gestational Age: Efficacy, Safety, and Pharmacokinetics

Recruiting· Changchun GeneScience Pharmaceutical Co., Ltd. logo

Changchun GeneScience Pharmaceutical Co., Ltd.·Phase 2·NCT07260500·72 enrolled

Short stature1 trial

The Dosage Exploration Study of PEG-rhGH for Treating Short Stature in Prepubertal and Pubertal Children

Not yet recruiting·SSecond Affiliated Hospital of Wenzhou Medical University·N/A·NCT06768411·240 enrolled

Cognitive Development1 trial

A Real World Study of the Effect of Early PEG-rhGH Therapy on Cognitive Development of SGA Infants

Recruiting·TTongji Hospital·Phase 4·NCT05144035·138 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for PEG-rhGH. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PEG-rhGH compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PEG-rhGH. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Changchun GeneScience Pharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Changchun GeneScience Pharmaceutical Co., Ltd.

PEG-rhGH

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Small for gestational age1 trial

Short stature1 trial

Cognitive Development1 trial

References

Drug Info

Quick Facts

Related News